Dana-Farber Cancer Institute (Head and Neck Cancer Treatment Center)
Welcome,         Profile    Billing    Logout  
 1 Trial 
21 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Hanna, Glenn J
ADAM, NCT03271372: Adjuvant Avelumab in Merkel Cell Cancer

Calendar Jan 2024 - Dec 2024: From trial
Active, not recruiting
3
101
US
Avelumab, Bavencio, MSB-0010718C, MSB0010718C, Peripheral Blood Collection, Placebo, placebo therapy, PLCB, normal saline solution
University of Washington, EMD Serono
Stage III Merkel Cell Carcinoma AJCC v8, Stage IIIB Merkel Cell Carcinoma AJCC v8, Stage IIIA Merkel Cell Carcinoma AJCC v8
04/26
02/29
NCT03341936: Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in SCCHN

Active, not recruiting
2
29
US
Nivolumab, Lirilumab
Dana-Farber Cancer Institute, Bristol-Myers Squibb
Squamous Cell Carcinoma of the Head and Neck
07/21
07/26
NCT03692325: Safety and Efficacy of Nivolumab in Treating Oral Proliferative Verrucous Leukoplakia

Completed
2
33
US
Nivolumab, Opdivo
Dana-Farber Cancer Institute, Bristol-Myers Squibb
Leukoplakia, Oral
09/22
08/24
NCT05057247: Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC

Active, not recruiting
2
26
US
Duvelisib, VS-0145, Docetaxel, Taxotere
Glenn J. Hanna, Secura Bio, Inc.
Squamous Cell Carcinoma of the Head and Neck (SCCHN), Recurrent Squamous Cell Carcinoma of the Head and Neck, Metastatic Head and Neck Cancer, Advanced Head and Neck Cancer, Advanced Head and Neck Squamous Cell Carcinoma
10/23
01/25
NCT05010629: 9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma

Active, not recruiting
2
35
US
9-ING-41, Carboplatin, Paraplatin
Glenn J. Hanna, Actuate Therapeutics Inc.
Salivary Gland Cancer, Recurrent Salivary Gland Cancer, Metastatic Cancer, Adenoid Cystic Carcinoma
06/24
08/25
QUILT-505, NCT06239220: PD-L1 T-haNK, N-803 IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC

Recruiting
2
25
US
PD-L1 t-haNK, NK-92, Cetuximab, Erbitux, N-803, Interleukin-15, IL-15, Anktiva
Glenn J. Hanna, ImmunityBio, Inc.
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer, Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
07/25
01/27
NCT05074940: Amivantamab in Adenoid Cystic Carcinoma

Recruiting
2
18
US
Amivantamab
Trisha Wise-Draper
Salivary Gland Cancer
08/24
08/28
NCT04620187: Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas

Recruiting
2
55
US
Ado-trastuzumab (T) emtansine (T-DM1), Kadcyla, Standard of Care Radiotherapy, Radiation, Standard of Care Chemotherapy, Cisplatin, carboplatin
Dana-Farber Cancer Institute, Genentech, Inc.
Salivary Gland Cancer, HER2 Gene Mutation
02/25
02/26
INTERCEPT, NCT06623110: Phase II Study of RP2 As Immunoprevention in High-Risk Oral Precancerous Disease

Not yet recruiting
2
25
US
RP2 Injection
Glenn J. Hanna, Replimune Inc.
High-Risk Oral Precancerous Disease
01/26
01/28
NCT05904080: Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer

Recruiting
2
50
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cabozantinib S-malate, BMS-907351, Cabometyx, Cometriq, XL 184, XL-184, XL184, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS 734016, BMS-734016, BMS734016, Ipilimumab Biosimilar CS1002, MDX 010, MDX-010, MDX-CTLA4, MDX010, Yervoy, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo
National Cancer Institute (NCI)
Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Stage IV Nasopharyngeal Carcinoma AJCC v8
06/28
06/28
CONTRAC, NCT04339062: Cemiplimab in AlloSCT/SOT Recipients With CSCC

Active, not recruiting
1/2
12
US
Cemiplimab, Libtayo, Everolimus, Afinitor, Zortress, Sirolimus, Rapamune, Prednisone, Deltasone, Prednicot, predniSONE Intensol, Rayos, Sterapred, Sterapred DS
Dana-Farber Cancer Institute, Regeneron Pharmaceuticals
Cutaneous Squamous Cell Carcinoma, Advanced Cancer
06/23
01/25
PRESERVE-001, NCT04140526: Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

Recruiting
1/2
733
US, RoW
ONC-392, A humanized anti-CTLA4 IgG1 monoclonal antibody made by OncoC4, Inc., Pembrolizumab, Keytruda, MK3475, Docetaxel, Taxotere, Docefrez
OncoC4, Inc., National Cancer Institute (NCI)
Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma, Metastatic Head and Neck Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Colorectal Cancer, Sarcomas, Metastatic Prostate Cancer, Ovarian Cancer, Small Cell Lung Cancer, Metastatic Breast Cancer, Pancreas Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Cervical Cancer, Adenoid Cystic Carcinoma, Salivary Gland Cancer, Urothelial Carcinoma
06/26
12/27
NCT05774899: CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC

Active, not recruiting
1/2
10
US
CB-103, Abemaciclib, Lenvatinib, Lenvima
Glenn J. Hanna, Adenoid Cystic Carcinoma Research Foundation, Cellestia Biotech AG
Adenoid Cystic Carcinoma, Metastatic Adenoid Cystic Carcinoma, Recurrent Adenoid Cystic Carcinoma
06/25
06/26
KURRENT-HN, NCT04997902: Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

Recruiting
1/2
40
US
Tipifarnib, Alpelisib, BYL719
Kura Oncology, Inc.
HNSCC
09/24
09/24
BA3011-001, NCT03425279: CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma

Recruiting
1/2
300
US, RoW
CAB-AXL-ADC, PD-1 inhibitor
BioAtla, Inc.
Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma
12/24
12/24
NCT05941507: A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors

Recruiting
1/2
300
Canada, US
LCB84, Anti-PD-1 monoclonal antibody
LigaChem Biosciences, Inc., AntibodyChem Biosciences, Inc.
Advanced Solid Tumors
01/27
05/27
NCT04290546: CIML NK Cell in Head & Neck Cancer

Active, not recruiting
1
11
US
Interleukin-15 Superagonist (N-803), CIML NK cell Infusion, cytokine induced memory-like natural killer, Ipilimumab, CTLA-4 inhibitor, Cetuximab, EGFR inhibitor
Dana-Farber Cancer Institute, Altor BioScience, Bristol-Myers Squibb, Miltenyi Biomedicine GmbH
Squamous Cell Carcinoma of the Head and Neck, Recurrent Head and Neck Squamous Cell Carcinoma
09/24
12/24
NCT06451497: Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

Recruiting
1
33
US
ZM008, Antibody
Zumutor Biologics Inc.
Non Small Cell Lung Cancer, Esophageal Cancer, Head and Neck Squamous Cell Carcinoma, Pancreas Adenocarcinoma, Biliary Tract Cancer, Prostate Cancer, Urothelial Carcinoma, Colorectal Cancer, Triple Negative Breast Cancer, High Grade Ovarian Serous Adenocarcinoma, Diffuse Large B Cell Lymphoma
12/26
04/27
NCT05553782: Drug Screening Using Novel IMD in ACC and Salivary Cancers

Not yet recruiting
1
20
US
Implantable Microdevice (IMD)
Dana-Farber Cancer Institute, Adenoid Cystic Carcinoma Research Foundation
Adenoid Cystic Carcinoma, Adenoid Cystic Carcinoma of the Salivary Gland
10/24
01/25
KEYNOTE-E28, NCT04429542: Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients with EGFR-driven Advanced Solid Tumors

Recruiting
1
292
Canada, US, RoW
BCA101, Pembrolizumab
Bicara Therapeutics, Merck Sharp & Dohme LLC
Head and Neck Squamous Cell Carcinoma, Squamous Cell Carcinoma of Anal Canal, Colorectal Cancer, Squamous Cell Carcinoma of the Lung, EGFR Amplification, Epithelial Ovarian Cancer, Pancreas Cancer, Cutaneous Squamous Cell Carcinoma, Head and Neck Neoplasms, Carcinoma, Squamous Cell, Squamous Cell Carcinoma of Head and Neck
12/26
06/27
REM-422-101, NCT06118086: Study of REM-422 in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma

Recruiting
1
65
US
REM-422
Remix Therapeutics
Adenoid Cystic Carcinoma, Metastatic Adenoid Cystic Carcinoma, Recurrent Adenoid Cystic Carcinoma
06/25
06/26

Download Options